Clinical

  1. Clinical

Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials

DURHAM, N.C. and BEIJING, June 7, 2024. Brii Biosciences Limited (“Brii Bio,” “we,” or the “Company”), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, presented new data from two Phase 2 studies evaluating BRII-179 either as a combination therapy with BRII-835 (elebsiran) or as an add-on […]
Written by
  1. Clinical

AbbVie Announces Positive Topline Results from Phase 2 Trial Evaluating Elahere for High Folate Receptor-Alpha Expressing Platinum-Sensitive Ovarian Cancer

NORTH CHICAGO, Ill., June 6, 2024. AbbVie announced today positive topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine (ELAHERE) monotherapy in heavily pre-treated patients with folate receptor-alpha (FRα) positive, platinum-sensitive ovarian cancer (PSOC). The study met its primary endpoint with an objective response rate (ORR) of 51.9% (95%CI 40.4 – 63.3%). […]
Written by
  1. Clinical

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

SOUTH SAN FRANSCISO, Calif., June 04, 2024. Surrozen, Inc. (“Surrozen” or the “Company”), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that the first patient has been dosed in its Phase 1b clinical trial for SZN-043 in patients with severe alcohol-associated hepatitis. The Phase 1b […]
Written by
  1. Clinical

Novartis Phase III Data Confirm Sustained Efficacy and Long-Term Safety of Oral Remibrutinib in Chronic Spontaneous Urticaria

Basel, May 31, 2024 – Novartis today announced new data that confirm the long-term efficacy and safety of remibrutinib, a highly selective Bruton’s tyrosine kinase (BTK) inhibitor, in chronic spontaneous urticaria (CSU)1. In the pivotal Phase III studies, REMIX-1 and REMIX-2, remibrutinib treatment showed significant symptom improvement early, which was sustained up to Week 52, […]
Written by
  1. Clinical

Avirmax Biopharma Inc. Receives IND Approval for Phase I/IIa Trial to Treat Wet AMD including PCV

HAYWARD, Calif., May 30, 2024. Avirmax Biopharma, Inc., a leading innovator in genetic medicines, is pleased to announce that it has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase I/IIa clinical trial for its gene therapy treatment targeting wet Age-related Macular Degeneration (AMD) including Polypoidal […]
Written by
  1. Clinical

Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndrome

MELBOURNE, Australia, May 27, 2024. Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). Statistically significant improvement from baseline was observed by both clinicians and caregivers from treatment, across all 4 efficacy measures that were specifically designed to assess the core […]
Written by
  1. Clinical

HI-Bio Announces Positive Results from Phase 2 Study of Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients

SOUTH SAN FRANCISCO, Calif., May 25, 2024. Human Immunology Biosciences (HI-Bio), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced positive results from a Phase 2 investigator-sponsored clinical trial of felzartamab for late antibody-mediated rejection (AMR) in kidney transplant recipients. Felzartamab is an investigational monoclonal antibody designed to […]
Written by
  1. Clinical

Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of Afuresertib PLUS LAE001 for the Treatment of Prostate Cancer

SHANGHAI and WARREN, N.J., May 23, 2024. Laekna, Inc., a science-driven, clinical-stage biotechnology company, announced that the company has received approval from the U.S. Food and Drugs Administration for the protocol of the phase III clinical trial of LAE002 (afuresertib, an AKT inhibitor) plus LAE001 (CYP17A1/CYP11B2 dual inhibitor) (“LAE201”)in patients with metastatic castration-resistant prostate cancer […]
Written by
  1. Clinical

New Results From Rilzabrutinib Phase 2 Study Show Potential to be First Advanced Oral Treatment for Moderate-to-Severe Asthma

Paris, May 22, 2024. Encouraging results from a phase 2 study showed that treatment with oral rilzabrutinib at both high dose and low doses led to a numerical reduction in loss of asthma control (LOAC) events (the primary endpoint) and improvements in symptoms in adult patients with uncontrolled moderate-to-severe asthma. These results were presented today […]
Written by
  1. Clinical

New Research Reveals Novel Neuroprotective Drug Candidate Meets Main Endpoint in Sufferers with Gentle to Average Alzheimer’s Illness

NEW YORK, Could 17, 2024. A examine revealed in the present day in Nature Drugs discovered {that a} novel neuroprotective drug candidate, LM11A-31, was secure and well-tolerated following dosing for 26 weeks in sufferers with gentle to reasonable Alzheimer’s illness. LM11A-31 additionally slowed the development of a number of spinal fluid and imaging biomarkers. These […]
Written by

Good Reads

A proteome-wide yeast degron collection for the dynamic study of protein function

Genome-wide collections of yeast strains, known as libraries, revolutionized the way systematic studies are carried out. Specifically, libraries that involve a cellular perturbation, such as the deletion collection, have facilitated key biological discoveries. However, short-term rewiring and long-term accumulation of suppressor mutations often obscure the functional consequences of such perturbations. We present the AID library […]
Written by

Columbia Climate School Hosts Ninth Annual Sustainability Careers Reception – State of the Planet

Practitioners who attended the 2024 Sustainability Careers Reception. (*See below for names and affiliations) Last month, the Columbia Climate School hosted its ninth annual Sustainability Careers Reception at the Columbia Club in Midtown Manhattan. Thirty-three sustainability professionals and 88 Columbia students from varying backgrounds and degree pursuits gathered to discuss the ever-pressing challenges and real-world […]
Written by

Worlwide

A proteome-wide yeast degron collection for the dynamic study of protein function

Genome-wide collections of yeast strains, known as libraries, revolutionized the way systematic studies are carried out. Specifically, libraries that involve a cellular perturbation, such as the deletion collection, have facilitated key biological discoveries. However, short-term rewiring and long-term accumulation of suppressor mutations often obscure the functional consequences of such perturbations. We present the AID library […]
Written by

Columbia Climate School Hosts Ninth Annual Sustainability Careers Reception – State of the Planet

Practitioners who attended the 2024 Sustainability Careers Reception. (*See below for names and affiliations) Last month, the Columbia Climate School hosted its ninth annual Sustainability Careers Reception at the Columbia Club in Midtown Manhattan. Thirty-three sustainability professionals and 88 Columbia students from varying backgrounds and degree pursuits gathered to discuss the ever-pressing challenges and real-world […]
Written by
Scientists uncover new way viruses fight back against bacteria

Conserving high-elevation grasslands in Peru is key to protect Andean bears

Andean bears carefully select the best foraging locations and plants to maximize nutrition and avoid livestock, according to a study publishing December 18, 2024, in the open-access journal PLOS ONE by Nicholas Pilfold at the San Diego Zoo Wildlife Alliance in California, U.S., and colleagues. Andean bears, also known as ‘spectacled bears’ because of the […]
Written by

Trending

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.